Cancer combo trial for brain metastases ends early after enrolling just one person
NCT ID NCT05553522
First seen Jan 04, 2026 · Last updated May 17, 2026 · Updated 19 times
Summary
This early-phase study tested whether combining three drugs (tucatinib, trastuzumab, capecitabine) with precise radiation could control brain tumors from HER2-positive breast cancer. Only one person enrolled before the trial was stopped. The main goal was to check safety and side effects, not to measure long-term benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176, United States
Conditions
Explore the condition pages connected to this study.